Repligen SEC Filings

Repligen Corporation director reported several transactions in company stock. On 11/13/2025, the director sold multiple blocks of common stock in open-market transactions at weighted average prices ranging from $151.01 to $157.11, each sale covering different share amounts. After these sales, the director beneficially owned 80,743 shares of Repligen common stock in direct form. The director also exercised a stock option for 2,952 shares at an exercise price of $33.87, which increased directly held shares while reducing the option position.

Repligen (RGEN) reported an insider transaction by a director on 11/12/2025. The director exercised 25,000 stock options at $33.87 and, on the same day, sold 25,000 common shares in multiple trades under a Rule 10b5-1 plan adopted on December 9, 2024. Sale prices were reported as weighted averages ranging from $154.92 to $158.51.

Following these transactions, the director directly owned 100,743 shares. The option reported expires on 03/01/2028, with 157,344 derivative securities beneficially owned after the transactions, and remaining tranches vesting 28,777 on 03/01/2026 and 28,778 on 03/01/2027.

Repligen Corporation reported Q3 2025 results with total revenue of $188.8 million and net income of $14.9 million, a turnaround from a $0.7 million loss a year ago. For the first nine months of 2025, revenue reached $540.3 million with net income of $35.6 million.

Cash and cash equivalents were $748.7 million, supporting a strong balance sheet with total assets of $2.92 billion. The company closed the 908 Devices bioprocessing analytics portfolio acquisition for $69.9 million in cash, recording provisional goodwill of $50.1 million and incurring $10.5 million in transaction and integration costs year to date. Contingent consideration fell to $7.6 million, producing gains of $4.1 million in Q3 and $12.1 million year to date.

The restructuring plan was completed in Q2 2025, with $4.1 million in related charges in the first nine months of 2025. The 1.00% Convertible Senior Notes due 2028 had a $537.9 million carrying amount and were not convertible for Q4 2025 under the indenture’s trading condition. Shares outstanding were 56,290,749 as of October 31, 2025.

Repligen Corporation filed an 8-K stating it announced financial results for the third quarter ended September 30, 2025. The company furnished the full text of the announcement as Exhibit 99.1, a press release dated October 28, 2025.

The information provided under Item 2.02 is furnished and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference, except as expressly set forth by specific reference.

Repligen Corporation reporting person Olivier Loeillot, who is listed as both a Director and the Chief Executive Officer, recorded a sale of common stock on 10/02/2025. The filing shows 1,248 shares were disposed of at a price of $145.23 per share, with 42,939 shares remaining beneficially owned after the transaction. The reported sale represents shares withheld by the issuer to satisfy tax withholding obligations arising from the release of restricted stock units, not an open-market purchase or voluntary sale. The Form 4 was signed on 10/06/2025 by an attorney-in-fact on behalf of the reporting person.

Repligen Corp (RGEN) Chief Financial Officer Jason K. Garland reported a non-derivative disposition on 09/25/2025 involving 412 shares of Common Stock sold at a price of $121.68 per share. The filing shows 13,383 shares remained beneficially owned by the reporting person after the transaction. The form identifies the transaction as related to tax withholding: the 412 shares were withheld by the issuer to satisfy the reporting person's tax withholding obligations upon the release of restricted stock units.

Repligen Corp (RGEN) director Anthony Hunt exercised options and sold shares on 09/10/2025 under a documented plan. Mr. Hunt exercised a stock option to acquire 20,000 shares at an exercise price of $33.87, resulting in 20,000 newly acquired shares recorded in Table II. On the same date he sold multiple blocks of common stock under a 10(b)5-1 trading plan, with weighted-average sale prices reported at $116.34, $118.32, $119.64, $120.19, $121.42 and $122.23 for different tranches. After these transactions his direct beneficial ownership of common stock is reported as 100,743 shares and he beneficially owns 182,344 shares underlying options.

Repligen Corp (RGEN) filed a Form 144 reporting a proposed sale of 29,111 common shares through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $3,508,378.25 and approximately 56,257,618 shares outstanding. The filing shows 9,111 shares acquired via restricted stock vesting on 03/01/2022 as compensation, and 20,000 shares associated with options (options granted 03/01/2018) to be sold on 09/10/2025 for cash. The filer reports no sales in the past three months. The notice includes the filer’s attestation that they are not aware of any undisclosed material adverse information about the issuer.

T. Rowe Price Associates, Inc. filed an Amendment No. 6 to Schedule 13G reporting ownership of 3,429,547 shares of Repligen Corp common stock, representing 6.1% of the class. The filing shows T. Rowe Price has sole voting power over 3,170,704 shares and sole dispositive power over 3,429,435 shares. No shared voting or dispositive power is reported.

The filer certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing lists Maryland as the filer’s place of organization and provides issuer and filer addresses.